In renal cell carcinoma patients, the use of anti-PD-L1 is significantly associated with an increased risk of all-grade TRAEs compared to anti-PD-1 (RR 0.45, 95 % CI 0.42–0.48, P < 0.0001), as shown in Fig. S8. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.